Guizhou Yibai Pharmaceutical (600594) Stock Overview
Researches, develops, produces, and sells novel pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
600594 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Guizhou Yibai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.15 |
| 52 Week High | CN¥5.27 |
| 52 Week Low | CN¥2.85 |
| Beta | 0.20 |
| 1 Month Change | -8.70% |
| 3 Month Change | -31.52% |
| 1 Year Change | -22.41% |
| 3 Year Change | -40.34% |
| 5 Year Change | -44.05% |
| Change since IPO | 28.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600594 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 6.1% | 7.2% | -1.1% |
| 1Y | -22.4% | -4.6% | 26.5% |
Return vs Industry: 600594 underperformed the CN Pharmaceuticals industry which returned -4.6% over the past year.
Return vs Market: 600594 underperformed the CN Market which returned 26.5% over the past year.
Price Volatility
| 600594 volatility | |
|---|---|
| 600594 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in CN Market | 11.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600594 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600594's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 4,832 | Ya Qi Dou | gzcci.com |
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells novel pharmaceutical products in China. The company offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, dripping pills, and oral solutions in the areas of tumor system, cerebrovascular and cardiovascular, respiratory system, rheumatic bone, digestive system, pediatric, anti-infection, anti-inflammatory, gynecological, tonic, oncology, orthopedics, gastroenterology, andrology and urology. Guizhou Yibai Pharmaceutical Co., Ltd.
Guizhou Yibai Pharmaceutical Co., Ltd. Fundamentals Summary
| 600594 fundamental statistics | |
|---|---|
| Market cap | CN¥2.47b |
| Earnings (TTM) | -CN¥349.70m |
| Revenue (TTM) | CN¥1.72b |
Is 600594 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600594 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.72b |
| Cost of Revenue | CN¥730.86m |
| Gross Profit | CN¥989.42m |
| Other Expenses | CN¥1.34b |
| Earnings | -CN¥349.70m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 21, 2026
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 57.52% |
| Net Profit Margin | -20.33% |
| Debt/Equity Ratio | 31.8% |
How did 600594 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/07 18:59 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guizhou Yibai Pharmaceutical Co., Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chi Man Wong | China Galaxy International Securities (Hong Kong) |
| Haigang Chen | China International Capital Corporation Limited |
| Jie Yao | Citic Securities Co., Ltd. |